埃克替尼靶向治疗非小细胞肺癌的近期疗效及对患者机体状态的影响  

Short-term efficacy of ectinib in targeted treatment of non-small cell lung cancer and its effect on the body status of patients

作　　者：阙晓梅 QUE Xiaomei(Department of Oncology,the Second Hospital of Longyan City,Fujian Province,Longyan 364000,China)

机构地区：[1]福建省龙岩市第二医院肿瘤内科,364000

出　　处：《临床合理用药杂志》2024年第23期21-24,28,共5页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的观察非小细胞肺癌采用埃克替尼靶向治疗的近期疗效及对患者机体状态的影响。方法选取2022年1月—2023年1月龙岩市第二医院收治的非小细胞肺癌患者68例,采用随机数字表法分为靶向药物治疗组(n=34)和常规化疗组(n=34)。常规化疗组采用吉西他滨联合顺铂化疗,靶向药物治疗组在常规化疗组治疗的基础上给予埃克替尼化疗。比较2组近期疗效、肿瘤标志物、免疫功能指标、疗效指标、营养状况及不良反应。结果靶向药物治疗组客观缓解率高于常规化疗组(73.53%vs.47.06%,χ^(2)=4.976,P=0.026)。治疗后,2组CEA、SCC及CA125水平低于治疗前,且靶向药物治疗组低于常规化疗组(P<0.05或P<0.01)。治疗后,常规化疗组CD4^(+)与治疗前比较差异不大(P>0.05),靶向药物治疗组CD4^(+)高于治疗前及常规化疗组(P<0.01);2组CD8^(+)均高于治疗前,但靶向药物治疗组CD8^(+)低于常规化疗组(P<0.05或P<0.01);2组CD4^(+)/CD8^(+)高于治疗前,且靶向药物治疗组高于常规化疗组(P<0.05或P<0.01)。靶向药物治疗组症状缓解时间较常规化疗组更短,疾病进展时间较常规化疗组更长(P<0.05或P<0.01)。治疗后,2组BMI、PA、Alb及Hb水平高于治疗前,且靶向药物治疗组更高(P<0.05或P<0.01)。靶向药物治疗组与常规化疗组治疗期间不良反应总发生率比较差异不大(50.00%vs.32.35%,χ^(2)=2.186,P=0.139)。结论埃克替尼靶向治疗非小细胞肺癌的客观缓解率更高,可明显降低肿瘤因子水平,提高机体免疫力与营养水平,有利于延长患者生存时间,并且不良反应发生率未见显著上升。Objective To observe the short-term efficacy of ectinib in the treatment of non-small cell lung cancer(NSCLC)and its effect on the body status of patients.Methods A total of 68 patients with non-small cell lung cancer admitted to the Second Hospital of Longyan City from January 2022 to January 2023 were selected and divided into targeted therapy group(n=34)and conventional chemotherapy group(n=34)by random number table method.The conventional chemotherapy group received gemcitabine combined with cisplatin,and the targeted therapy group received ectinib chemotherapy on the basis of the conventional chemotherapy group.The short-term efficacy,tumor markers,immune function indexes,efficacy indexes,nutritional status and adverse reactions were compared between the two groups.Results The objective response rate of the targeted therapy group was higher than that of the conventional chemotherapy group(73.53%vs.47.06%,χ^(2)=4.976,P=0.026).After treatment,CEA,SCC and CA125 levels in two groups were lower than before treatment,and those in targeted therapy group were lower than those in conventional chemotherapy group(P<0.05 or P<0.01).After treatment,there was no significant difference in CD4^(+)between conventional chemotherapy group and before treatment(P>0.05),and CD4^(+)in targeted therapy group were higher than before treatment and conventional chemotherapy group(P<0.01).CD8^(+)in two groups were higher than before treatment,but CD8^(+)in targeted therapy group was lower than that in conventional chemotherapy group(P<0.05 or P<0.01).CD4^(+)/CD8^(+)in two groups were higher than before treatment,and the targeted therapy group was higher than the conventional chemotherapy group(P<0.05 or P<0.01).The duration of symptom remission in the targeted therapy group was shorter than that in the conventional chemotherapy group,and the duration of disease progression was longer than that in the conventional chemotherapy group(P<0.05 or P<0.01).After treatment,the levels of BMI,PA,Alb and Hb in two groups were higher than before

关 键 词：非小细胞肺癌 埃克替尼 靶向治疗 机体状态 

分 类 号：R734.2[医药卫生—肿瘤]